Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SurModics Pharmaceuticals, a provider of drug delivery and surface modification technologies to the healthcare industry, said that its unit has licensed certain of its biodegradable polymer implant technology to Clinuvel Pharmaceuticals for the treatment of sun-induced skin disorders, under a license agreement signed between the two firms.
Subscribe to our email newsletter
SurModics and Clinuvel are into a collaboration for the development of Clinuvel’s sustained release Scenesse (afamelanotide) implant formulation from several years.
The implant is being developed as a prophylactic treatment for a range of UV and light-related skin disorders.
Clinuvel’s implant is currently being evaluated for a variety of skin disorders in several clinical trials in Europe and Australia. Clinuvel has commenced Phase II trial in the US for the treatment of erythropoietic protoporphyria (EPP).
SurModics’ biodegradable polymer drug delivery technology enables the drug afamelanotide to be released in a sustained and tightly controlled manner.
Phil Ankeny, interim CEO of SurModics, said: “This announcement demonstrates the value of our sustained drug delivery technologies and reinforces how we partner with our customers to develop and bring to market compelling products that leverage our core technologies.
“It also further validates the progress we are making in securing license agreements with our customers for pharmaceutical products that incorporate technology developed by our SurModics Pharmaceuticals business. Additionally, Clinuvel has become yet another potential customer for our new cGMP manufacturing facility in Alabama.”
Philippe Wolgen, CEO of Clinuvel, said: “The launch of our clinical trial program for porphyria in the US is a significant milestone for our company, and our partnership. We look forward to continuing our work together to develop effective therapies for patients suffering from severe UV-related skin disorders.”